EarliPoint
FDA-cleared eye-tracking platform for autism diagnosis and objective clinical assessment in young children.
Not published · contact vendor
Diagnostic programs · Objective assessment and progress context · Multidisciplinary clinics
VERIFICATION IN PROGRESS
Strengths
- Backed by successive FDA clearances (2022, 2023, 2025) rather than a single authorization
- Objective, biomarker-style measurement in a field of subjective instruments
- Deployed at major institutions including Marcus Autism Center
Trade-offs
- Device procurement and program design make this an implementation decision, not a software trial
- Pricing not published
EarliPoint — from EarliTec Diagnostics, which rebranded as EarliPoint Health — is an FDA-cleared eye-tracking platform supporting clinicians in diagnosing and assessing autism in young children, cleared for use in children as young as 16 months. Its clearances have come in successive waves (2022, a next-generation clearance in 2023, and a further expansion in 2025), and deployments include institutions like Marcus Autism Center, with a $21.5M Series B funding commercialization.
The important nuance for ABA organizations: EarliPoint’s positioning is broader than initial diagnosis. Objective, repeatable measurement has obvious roles across the care journey — assessment context at intake, severity characterization, and the company’s stated vision points toward supporting ongoing autism care rather than a one-time diagnostic event. For practices weighing diagnostic capacity, that reframes the question from “should we offer diagnosis” to “what does objective measurement change about our clinical model” — with wait-time reduction for families as the immediate, concrete win.
Where it fits
For ABA organizations weighing whether to add diagnostic and assessment capacity, EarliPoint is the flagship of the objective-measurement approach — the strategic questions are program design: who evaluates, who refers, how measurement informs care planning, and how diagnosis connects to starting services sooner.
What is EarliPoint?
EarliPoint is fDA-cleared eye-tracking platform for autism diagnosis and objective clinical assessment in young children. It is listed in the Diagnostics & Assessment category of The ABA Index.
How much does EarliPoint cost?
EarliPoint does not publish pricing publicly — quotes come directly from the vendor. The ABA Index tracks pricing transparency for every listing and reports unpublished pricing as exactly that, never a guessed number.
Who is EarliPoint best for?
Based on its positioning and documented use: Diagnostic programs; Objective assessment and progress context; Multidisciplinary clinics.
What are alternatives to EarliPoint?
Other tools in the Diagnostics & Assessment category include ABLLS-R, ADOS-2, AFLS, As You Are. Each has an independent profile on The ABA Index.
ABLLS-R
Partington's criterion-referenced assessment of basic language and learner skills across 25 skill areas.
ADOS-2
The semi-structured, standardized diagnostic observation widely treated as the gold standard in autism evaluation.
AFLS
Assessment of Functional Living Skills — practical independence skills across home, school, and community.
As You Are
Virtual clinic providing telehealth autism diagnostic evaluations for children.
See something outdated or wrong? This profile is maintained independently — vendors and users can request corrections and we verify against primary sources.
Request a correction